About the Combination

Q1. What is happening?

 Veristat has signed an agreement to acquire Certara’s Regulatory and Medical Writing business, a team known for its white-glove advisory services and deep expertise in authoring clinical and non-clinical documents throughout the drug development lifecycle. This combination brings together two best-in-class organizations with shared values, complementary capabilities, and a shared commitment to helping clients bring life-saving therapies to patients.

Q2. Can you tell me more about Certera's Regulatory and Medical Writing Business? 

 Certara’s Regulatory and Medical Writing business specializes in regulatory writing, submission leadership, safety writing, CMC services, and regulatory operations. Their team of 230 experts, operating across approximately 10 countries — has authored more than 60,000 documents over the past four years and holds preferred status with 20 of the top 30 global pharmaceutical companies. More than 60% of their writers hold advanced degrees, with an average of over 10 years of experience. 

Q3. Why did Veristat pursue this acquisition?

 Veristat was founded by a medical writer and a biostatistician. The work their team does, regulatory writing, submission leadership, and deep scientific expertise throughout the development lifecycle, is foundational to who we are. By coming together, we are strengthening our core capabilities and becoming the clear leader in biostatistics, medical writing, and regulatory affairs. For our clients, this means access to a broader team, more geographic coverage, and deeper expertise, all under one roof. 

Q4. What will the combined company be called?

 The combined organization will operate under the Veristat name. Certara's remaining businesses will continue to operate independently under the Certara brand. This transaction is specific to Certara’s Regulatory and Medical Writing business only. 

Q5. When will the transaction close?

The transaction is expected to close in the second quarter of 2026. Until then, Veristat and CRS will continue to operate as separate and independent businesses. We will update this page when the transaction is complete.

For Current and Prospective Clients

Q6. Does this change how I work with Veristat?

No. Until the transaction closes, both companies continue to operate independently and nothing changes about how you engage with Veristat. After close, your existing team remains in place and your projects continue as normal. We will proactively reach out if there is anything you need to know.

Q7. Will my contract or pricing change?

No. There are no changes to existing contracts or pricing as a result of this transaction. If anything relevant to your engagement changes, your account team will contact you directly.

Q8. How will this benefit me as a client?

 In the near term, your projects and team will remain unchanged. Over time, you will benefit from a significantly expanded bench of regulatory and medical writing expertise, a global team operating across more time zones for faster turnaround, and the ability to access integrated services. From early strategic consulting through regulatory submission, we will be your single, trusted partner relationship. Veristat has contributed to approximately 8% of all novel therapy approvals in 2025 and 11% of NME approvals over the past 10 years. As a combined organization, we expect to accelerate that further. 

Q9. I work with Certera's Regulatory and Medical Writing team — does anything change for me?

 Until the transaction closes, their team will operate exactly as they do today. As the integration progresses, clients will have access to Veristat's broader platform, including clinical operations, biostatistics, and regulatory strategy — while retaining the same expert team they have worked with. We are committed to a thoughtful, non-disruptive integration. 

Q10. Who should I contact with questions?

 Please reach out to your existing account contacts with any questions. You can also contact us at integrationcrs@veristat.com. For media inquiries, please contact Lisa Barbadora at lbarbadora@barbadoraink.com. 

About Veristat

Q11. What does Veristat do?

Veristat is a full-service CRO and consultancy that helps life sciences companies bring novel therapies to market. Founded in 1994 by a medical writer and a biostatistician, we have supported more than 1,500 clinical trials and consulting projects, contributed to over 105 regulatory approvals — 70+ in rare disease — and supported clients in rare disease, oncology, neurology, and advanced therapies across more than 100 countries. We operate globally with offices in North America, Europe, and Asia.

Q12. What is Veristat's track record with acquisitions?

Under WindRose Health Investors' ownership, Veristat has completed four strategic acquisitions across Europe and Asia. Each acquisition has expanded our geographic footprint and capability set while maintaining our commitment to team continuity and client service quality. We have a proven approach to integration — welcoming teams and preserving what makes them excellent while building the infrastructure to grow together.

Please read the full press release here: https://www.businesswire.com/news/home/20260422264798/en/Veristat-to-Acquire-Certaras-Regulatory-and-Medical-Writing-Business 

Media Contact:

Lisa Barbadora, Barbadora INK for Veristat +1 (610) 420-3413 lbarbadora@barbadoraink.com